![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
HuidaGene Therapeutics
Company Type: Therapeutics
Main focus: Development of novel genomic medicines for diverse diseases
Company stage: Clinical
Diseases: Ophthalmology, neurology, neuro-myology, otology and neurology
Genome-editing tool: CRISPR-Cas12 and CRISPR-Cas13
Funding stage: Series C
Location: Shangay, China
Website: https://www.huidagene.com/
Pipeline:https://www.huidagene.com/program-pipeline/pipeline
Partners:
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_huidegene_66ad832573_c4f663fe81.jpg)
HuidaGene is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing gene-editing tools and gene therapies develop novel genetic medicines. Based in Shanghai and New Jersey, HuidaGene is addressing patients’ needs globally with various therapeutic programmes spanning ophthalmology, neurology, neuro-myology, otology and neurology.